Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation
about
Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects.T-cell immunotherapy: looking forward.Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients.In vitro immunotherapy potency assays using real-time cell analysis.
P2860
Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Regulation of immunotherapeuti ...... opment and clinical evaluation
@ast
Regulation of immunotherapeuti ...... opment and clinical evaluation
@en
Regulation of immunotherapeuti ...... opment and clinical evaluation
@nl
type
label
Regulation of immunotherapeuti ...... opment and clinical evaluation
@ast
Regulation of immunotherapeuti ...... opment and clinical evaluation
@en
Regulation of immunotherapeuti ...... opment and clinical evaluation
@nl
prefLabel
Regulation of immunotherapeuti ...... opment and clinical evaluation
@ast
Regulation of immunotherapeuti ...... opment and clinical evaluation
@en
Regulation of immunotherapeuti ...... opment and clinical evaluation
@nl
P2093
P2860
P356
P1476
Regulation of immunotherapeuti ...... opment and clinical evaluation
@en
P2093
Angelo R De Claro
Brian Niland
Marc Theoret
Peter F Bross
Raj K Puri
Ramjay S Vatsan
Syed R Husain
Whitney Helms
P2860
P2888
P356
10.1186/2051-1426-1-5
P407
P577
2013-01-01T00:00:00Z
P5875
P6179
1051748215